We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
ENHERTU AstraZeneca Pty Ltd
Product name
ENHERTU
Sponsor
Accepted date
Sep-2024
Active ingredients
trastuzumab deruxtecan
Proposed indication
Treatment of adult patients with metastatic NSCLC or NSCLC that cannot be removed surgically.
Application type
C (new indication)
Publication date
Sep-2024
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration.